Can Mindray Medical International Meet These Numbers?
Mindray Medical International (NYS: MR) is expected to report Q4 earnings on Feb. 25. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Mindray Medical International's revenues will increase 15.1% and EPS will increase 15.9%.
The average estimate for revenue is $304.1 million. On the bottom line, the average EPS estimate is $0.51.
Last quarter, Mindray Medical International booked revenue of $257.1 million. GAAP reported sales were 18% higher than the prior-year quarter's $218.4 million.
Last quarter, non-GAAP EPS came in at $0.42. GAAP EPS of $0.30 for Q3 were 3.2% lower than the prior-year quarter's $0.31 per share.
For the preceding quarter, gross margin was 56.0%, 110 basis points better than the prior-year quarter. Operating margin was 15.2%, 250 basis points worse than the prior-year quarter. Net margin was 13.9%, 320 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $1.06 billion. The average EPS estimate is $1.77.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 1,347 members out of 1,382 rating the stock outperform, and 35 members rating it underperform. Among 285 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 273 give Mindray Medical International a green thumbs-up, and 12 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Mindray Medical International is outperform, with an average price target of $35.51.
Is Mindray Medical International the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Mindray Medical International to My Watchlist.
The article Can Mindray Medical International Meet These Numbers? originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.